Work

Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.10029

Authors: Jason Alan Chesney, Igor Puzanov, Frances A. Collichio, Mohammed M. Milhem, Axel Hauschild, Min Yi, Sumita Bhatta, Rubina Ismail, Claus Garbe, Parminder Singh, Janice M. Mehnert

Institutions: University of Louisville, Vanderbilt University Medical Center, University of North Carolina at Chapel Hill, University of Iowa, University of Iowa Holden Comprehensive Cancer Center, University Hospital Schleswig-Holstein, Amgen (United States), University of Tübingen, Mayo Clinic Hospital, Rutgers Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Amgen

OpenAlex ID: W3031970601

Cites:

Cited by: 2

Related to: 10